We know that MRD is relevant, what next?
A Pharmacist's view on biosimilars
The future is bright for hematological oncology: promising areas for 2018 and beyond
CLL highlights from ASCO 2016: HELIOS trial, CAR T-cell therapy and CLL-IPI
Proton and photon therapy in managing hematological malignancies